BCRX

Biocryst Pharmaceuticals, Inc.

A biopharmaceutical company that develops medicines for rare diseases, BioCryst's flagship product is Orladeyo, an oral once-daily pill that prevents attacks of hereditary angioedema, a rare genetic condition causing sudden, painful swelling. Founded in 1986 in Birmingham, Alabama, the name blends "bio" with "cryst," a nod to the X-ray crystallography technique its scientists use to design drugs at the molecular level. The company also markets RAPIVAB, an antiviral treatment for influenza.

Recent Activity

Show $

2026Q2

1 sell

Bridgewater Associates LPTRIM

-147.0K shares(-23.0%)

Bridgewater Associates LPTRIM

-147.0K shares(-23.0%)

2026Q1

1 buy

Bridgewater Associates LPADD

+402.5K shares(+170.9%)

Bridgewater Associates LPADD

+402.5K shares(+170.9%)

Loading more activity...